<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109252</url>
  </required_header>
  <id_info>
    <org_study_id>ACD2391g</org_study_id>
    <nct_id>NCT00109252</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g</brief_title>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab Followed by Efalizumab Taper in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter study designed to evaluate the efficacy and safety of&#xD;
      efalizumab administered at weekly SC (subcutaneous) doses of 1.0 mg/kg followed by efalizumab&#xD;
      taper in subjects with plaque psoriasis who previously participated in Study ACD2390g.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>0</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raptiva (efalizumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Previous participation in Study ACD2390g&#xD;
&#xD;
          -  For women of childbearing potential, continued use of an acceptable method of&#xD;
             contraception for the duration of their participation in the study&#xD;
&#xD;
          -  Willingness to continue to hold sun exposure reasonably constant and to avoid use of&#xD;
             tanning booths or other UV light sources throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical condition that, in the judgment of the investigator, would jeopardize the&#xD;
             subject's safety following exposure to efalizumab&#xD;
&#xD;
          -  Systemic therapy for psoriasis (ET Day 0 through FU Day 84 or upon relapse or unusual&#xD;
             presentation of psoriasis in the FU period, whichever occurs first)&#xD;
&#xD;
          -  Systemic immunosuppressive drugs for other indications (ET Day 0 through FU Day 84)&#xD;
&#xD;
          -  Topical therapies for psoriasis (ET Day 0 through ET Day 84)&#xD;
&#xD;
          -  Live virus or bacteria vaccines (ET Day 0 through FU Day 84)&#xD;
&#xD;
          -  Other vaccines or allergy desensitization (it is recommended that these be scheduled&#xD;
             after FU Day 84)&#xD;
&#xD;
          -  Other experimental drugs or treatments (ET Day 0 through FU Day 84)&#xD;
&#xD;
          -  Beta-Blockers, ACE inhibitors, interferons, quinidine, antimalarial drugs, or lithium&#xD;
             (if clinically indicated, such medications are allowed but the dosage should be held&#xD;
             constant between ET Day 0 and TT Day 84)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 26, 2005</study_first_submitted>
  <study_first_submitted_qc>April 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2005</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plaque Psoriasis</keyword>
  <keyword>Topical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

